What is the recommended daily dose and usage of dasatinib?

Dasatinib is a second-generation BCR-ABL tyrosine kinase inhibitor that is widely used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The dosage should be determined taking into account the patient's stage of illness, age, weight, and whether he has received other treatments. Generally, the recommended daily dose is 100 mg orally once in adults with newly diagnosed chronic-phase Ph+CML, and 140 mg daily in patients with accelerated-phase, blast-phase CML, or Ph+ALL. The medicine must be swallowed whole and cannot be crushed, broken or chewed, and can be taken with or without food. However, it is recommended to take the medicine at the same time every day to ensure stable blood concentration.

Dosing for pediatric patients is more individualized. The dosage is divided based on body weight and needs to be adjusted regularly according to changes in body weight. For example, for children weighing between 10 and 20 kg, the recommended dose is 40 mg per day. As the weight increases, the dose is gradually increased until the maximum recommended dose of 100 mg is reached. Because pediatric patients may have difficulty swallowing, doctors may provide special recommendations for drug management based on the actual situation.

In addition, dasatinib has metabolic and absorption interactions with a variety of drugs, such as proton pump inhibitors, antifungal drugs or anti-tuberculosis drugs, which may affect its efficacy or increase toxicity. Patients must inform their doctor about all the medications they are taking when taking this product so that treatment strategies can be adjusted. During the medication period, blood routine, electrolytes and electrocardiogram should be checked regularly to monitor whether adverse reactions such as blood system suppression, fluid retention or QT interval prolongation occur.

Due to its complex mechanism of action, medication must be administered under the guidance of a doctor with experience in hematological tumors. Do not change the dosage or stop medication on your own. Overall, individualized management of dasatinib usage and dosage is the key to ensuring the effectiveness and safety of treatment.

Reference materials:https://go.drugbank.com/drugs/DB01254